Skip to Main Content

Paper Details

Identification of an "Exceptional Responder" Cell Line to MEK1 Inhibition: Clinical Implications for MEK-Targeted Therapy.
Mol Cancer Res
19
2016
cell_line 0 0.5155373215675354 CUI-less NULL NULL NULL NULL NULL NULL NULL pubmed22n0849.json
292418528 26582713 22 54 Exceptional Responder Cell Line, Cancers, Cas9, MAP2K1, MAP2K1 mutations, MAP2K1-mutant cell lines, MAPK, MEK, MEK1, NCI-H1437, NCI-H1437 cells, OCUM-1, Q56P, RAS, RNA, SNU-C1, cancer, cancer cell lines, cancers, cell lines, control cell lines, genomic, lung adenocarcinoma, lung adenocarcinoma cell line, lung cancer, lung cancer cell line, lung cancer cell lines, oncogenic, shRNA, trametinib, tumors
Author NameAffiliation
Aviad TsherniakBroad Institute of Harvard and MIT
Aviad TsherniakBroad Institute of Harvard and MIT
Francisca VazquezBroad Institute of Harvard and MIT, Dana-Farber Cancer Institute
Barbara A WeirBroad Institute of Harvard and MIT, Dana-Farber Cancer Institute
Barbara A WeirBroad Institute of Harvard and MIT, Dana-Farber Cancer Institute
William C HahnBroad Institute of Harvard and MIT, Dana-Farber Cancer Institute, Massachusetts. Center for Cancer Genome Discovery, Brigham and Women's Hospital, Harvard Medical School
William C HahnBroad Institute of Harvard and MIT, Dana-Farber Cancer Institute, Massachusetts. Center for Cancer Genome Discovery, Brigham and Women's Hospital, Harvard Medical School
Matthew MeyersonBroad Institute of Harvard and MIT, Dana-Farber Cancer Institute, Massachusetts. Center for Cancer Genome Discovery, Harvard Medical School
Matthew MeyersonBroad Institute of Harvard and MIT, Dana-Farber Cancer Institute, Massachusetts. Center for Cancer Genome Discovery, Harvard Medical School
  • 1 - 9

Datasets

Release 1.2